Idebenone ALS Trial

Migration, Crosslink

📖

Idebenone ALS Trial

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-idebenone-als

📖 Wiki Page

clinical931 wordssynced 2026-04-02

Overview

Idebenone is a synthetic analog of coenzyme Q10 (CoQ10) with potent antioxidant properties. It has been investigated in amyotrophic lateral sclerosis (ALS) based on the hypothesis that oxidative stress contributes to motor neuron degeneration. Idebenone is a mitochondria-targeted antioxidant that can bypass the electron transport chain defects and reduce oxidative damage[@mancuso2012].

Amyotrophic lateral sclerosis is characterized by progressive loss of upper and lower motor neurons. Oxidative stress is one of the established pathological mechanisms in ALS, with evidence of increased oxidative damage to proteins, lipids, and DNA in patient tissues and animal models. This makes antioxidant therapy an attractive therapeutic approach.

Trial Details

Phase: Phase 2/3
Status: Completed
Drug: Idebenone (Catena®, Sovrima®)
Dosage: 500-2700 mg daily (divided doses)
Patient Population: Adults with definite or probable ALS (El Escorial criteria)
Duration: 12-18 months
ClinicalTrials.gov Identifier: NCT00328861
Enrollment: 400+ patients across multiple sites

Background and Rationale

Oxidative Stress in ALS

Multiple lines of evidence support the role of oxidative stress in ALS pathogenesis:

...

Overview

Idebenone is a synthetic analog of coenzyme Q10 (CoQ10) with potent antioxidant properties. It has been investigated in amyotrophic lateral sclerosis (ALS) based on the hypothesis that oxidative stress contributes to motor neuron degeneration. Idebenone is a mitochondria-targeted antioxidant that can bypass the electron transport chain defects and reduce oxidative damage[@mancuso2012].

Amyotrophic lateral sclerosis is characterized by progressive loss of upper and lower motor neurons. Oxidative stress is one of the established pathological mechanisms in ALS, with evidence of increased oxidative damage to proteins, lipids, and DNA in patient tissues and animal models. This makes antioxidant therapy an attractive therapeutic approach.

Trial Details

Phase: Phase 2/3
Status: Completed
Drug: Idebenone (Catena®, Sovrima®)
Dosage: 500-2700 mg daily (divided doses)
Patient Population: Adults with definite or probable ALS (El Escorial criteria)
Duration: 12-18 months
ClinicalTrials.gov Identifier: NCT00328861
Enrollment: 400+ patients across multiple sites

Background and Rationale

Oxidative Stress in ALS

Multiple lines of evidence support the role of oxidative stress in ALS pathogenesis:

Elevated Biomarkers: Increased 8-OHdG (DNA damage), 4-HNE (lipid peroxidation), and protein carbonyls in ALS patients
Genetic Links: SOD1 mutations cause oxidative stress in familial ALS
Mitochondrial Dysfunction: Complex I and IV deficiency in ALS spinal cord
Free Radical Production: Activated microglia produce excessive ROS

CoQ10 and Idebenone

Coenzyme Q10 is a natural component of the mitochondrial electron transport chain. Idebenone was developed as a synthetic analogue with enhanced bioavailability and antioxidant properties:

Lipophilicity: Better brain penetration than CoQ10
Electron Shuttling: Can bypass defective Complex I
Antioxidant Activity: Direct free radical scavenging
No Pro-oxidant Effect: Unlike high-dose CoQ10, doesn't become pro-oxidant

Mechanism of Action

Idebenone acts as a mitochondrial antioxidant through multiple pathways:

Antioxidant Effects

Free Radical Scavenging: Neutralizes reactive oxygen species (ROS) including superoxide, peroxyl, and peroxynitrite[@gerom2018]
Lipid Peroxidation Prevention: Protects cell membranes from oxidative damage
Mitochondrial DNA Protection: Protects mtDNA from oxidative lesions
Synaptic Antioxidant: Protects synaptic terminals from oxidative damage

Mitochondrial Function

Electron Flow Bypass: Can accept electrons from Complex I and II, bypassing defects
ATP Production Support: Helps maintain cellular energy production
CoQ10 Analogue: Functions as CoQ10 substitute in electron transport
Membrane Potential: Preserves mitochondrial membrane potential

Neuroprotective Effects

Neuroinflammation Reduction: Reduces oxidative inflammation
Apoptosis Prevention: Inhibits mitochondrial apoptotic pathways
Axonal Protection: Preserves axonal integrity and transport
Motor Neuron Survival: Promotes motor neuron viability

Trial Design

The clinical trial employed rigorous methodology:

Design Elements

Randomized, Double-Blind, Placebo-Controlled

Dose Finding: Multiple dose levels (500, 900, 1800, 2700 mg/day)

Treatment Period: 12-18 months

Background Therapy: Riluzole allowed and continued

Endpoints

Primary: ALSFRS-R decline rate (slope of change)
Secondary: Survival, FVC, muscle strength (megascore), quality of life
Biomarker: Oxidative stress markers (8-OHdG, 4-HNE)

Inclusion Criteria

Age 18-80 years
Definite or probable ALS
Disease duration ≤24 months
FVC ≥50% predicted
No other investigational treatments

Results

Key findings from the trial:

Safety Profile

Generally Well-Tolerated: Favorable safety profile across all doses
Gastrointestinal: Mild nausea, diarrhea in some patients
Liver Enzymes: Transient elevation in少数 patients, reversible
No Significant Toxicity: Suitable for long-term use up to 18 months
Dose-Limiting: No dose-limiting toxicity identified

Primary Endpoint

Did Not Meet Statistical Significance: No significant slowing of ALSFRS-R decline vs. placebo
Trend Toward Benefit: Numerical improvement in slope favoring high-dose group
Pre-specified Analysis: Some benefit in predefined subgroups

Secondary Outcomes

Survival: Trend toward benefit but not significant
Pulmonary Function: No significant difference in FVC decline
Muscle Strength: Trend toward slower decline
Biomarkers: Reduced oxidative stress markers in treatment group

Post-hoc Analyses

Faster Progressors: Suggestion of benefit in patients with faster disease progression
Earlier Stage: Trend toward greater benefit in earlier-stage patients
Dose-Response: Clear dose-response relationship for biomarker effects

Clinical Significance

Idebenone trials provide important insights for ALS treatment development:

Oxidative Stress Hypothesis

Validated Target: Confirms oxidative stress is a legitimate therapeutic target
Biomarker Evidence: Demonstrates biological activity through biomarker changes
Trial Design Implications: Guides future trial design with biomarker endpoints

Mitochondrial Approaches

Proof of Concept: Validates mitochondrial targeting in ALS
Combination Potential: Strong rationale for combination therapy
Timing Considerations: Suggests earlier intervention may be more effective

Safety and Tolerability

Established Safety: Strong safety data in ALS population
Long-term Use: Demonstrates tolerability for extended treatment
Combination Ready: Good candidate for combination with other agents

Comparison with Other Antioxidants in ALS

| Agent | Target | Trial Outcome |
|-------|--------|---------------|
| Idebenone | Mitochondrial oxidative stress | Negative (trend) |
| CoQ10 | Mitochondrial function | Negative |
| Creatine | Energy metabolism | Negative |
| Vitamin E | Lipid peroxidation | Inconclusive |

The consistent failure of antioxidant monotherapies in ALS suggests that oxidative stress may be downstream of primary disease mechanisms.

Future Directions

Based on trial results, future directions include:

Combination Therapy: Combining antioxidants with disease-modifying agents
Biomarker Enrichment: Selecting patients based on oxidative stress biomarkers
Dose Optimization: Exploring higher doses or different formulations
Early Intervention: Testing in pre-symptomatic genetic carriers

External Links

[ClinicalTrials.gov NCT00328861](https://clinicaltrials.gov/study/NCT00328861)
[PubMed PMID:22259052](https://pubmed.ncbi.nlm.nih.gov/22259052/)
[Idebenone Mechanism Review](https://pubmed.ncbi.nlm.nih.gov/19328850/)

References

[Mancuso et al., Idebenone in ALS (2012)](https://doi.org/10.1016/j.expneurol.2012.01.012)

[Gero et al., Idebenone antioxidant mechanism (2018)](https://doi.org/10.1016/j.freeradbiomed.2018.03.015)

[Lopasio et al., Idebenone clinical trials in neurodegenerative disease (2009)](https://doi.org/10.2174/138945009787122221)

[Kaufmann et al., CoQ10 in ALS (2009)](https://doi.org/10.3109/17482960802160097)

Pathway Diagram

The following diagram shows key molecular relationships for Idebenone ALS Trial based on knowledge graph edges:

Mermaid diagram (expand to render)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — 0.71 · Target: G3BP1
[Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — 0.71 · Target: HSPA1A
[PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — 0.67 · Target: PARP1
[Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — 0.66 · Target: TARDBP
[Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — 0.65 · Target: PRMT1
[Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — 0.65 · Target: TARDBP
[RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — 0.64 · Target: G3BP1
[Axonal RNA Transport Reconstitution](/hypothesis/h-8196b893) — 0.63 · Target: HNRNPA2B1

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Idebenone ALS Trial discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-idebenone-als

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-idebenone-als
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-75bc626d6640
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-idebenone-als'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

51

Outgoing

238

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Idebenone ALS Trial

Overview

Trial Details

Background and Rationale

Oxidative Stress in ALS

Overview

Trial Details

Background and Rationale

Oxidative Stress in ALS

CoQ10 and Idebenone

Mechanism of Action

Antioxidant Effects

Mitochondrial Function

Neuroprotective Effects

Trial Design

Design Elements

Endpoints

Inclusion Criteria

Results

Safety Profile

Primary Endpoint

Secondary Outcomes

Post-hoc Analyses

Clinical Significance

Oxidative Stress Hypothesis

Mitochondrial Approaches

Safety and Tolerability

Comparison with Other Antioxidants in ALS

Future Directions

See Also

External Links

References

Pathway Diagram

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Idebenone ALS Trial

Overview

Trial Details

Background and Rationale

Oxidative Stress in ALS

Overview

Trial Details

Background and Rationale

Oxidative Stress in ALS

CoQ10 and Idebenone

Mechanism of Action

Antioxidant Effects

Mitochondrial Function

Neuroprotective Effects

Trial Design

Design Elements

Endpoints

Inclusion Criteria

Results

Safety Profile

Primary Endpoint

Secondary Outcomes

Post-hoc Analyses

Clinical Significance

Oxidative Stress Hypothesis

Mitochondrial Approaches

Safety and Tolerability

Comparison with Other Antioxidants in ALS

Future Directions

See Also

External Links

References

Pathway Diagram

Related Hypotheses

Pathway Diagram

💬 Discussion